CL2011000295A1 - Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar. - Google Patents

Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar.

Info

Publication number
CL2011000295A1
CL2011000295A1 CL2011000295A CL2011000295A CL2011000295A1 CL 2011000295 A1 CL2011000295 A1 CL 2011000295A1 CL 2011000295 A CL2011000295 A CL 2011000295A CL 2011000295 A CL2011000295 A CL 2011000295A CL 2011000295 A1 CL2011000295 A1 CL 2011000295A1
Authority
CL
Chile
Prior art keywords
pyrimidyl
benzamide
amino
treatment
compounds derived
Prior art date
Application number
CL2011000295A
Other languages
English (en)
Spanish (es)
Inventor
Steve Quinn Deborah Pascoe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41137217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000295(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2011000295A1 publication Critical patent/CL2011000295A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2011000295A 2008-08-13 2011-02-11 Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar. CL2011000295A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8838208P 2008-08-13 2008-08-13
US16450109P 2009-03-30 2009-03-30

Publications (1)

Publication Number Publication Date
CL2011000295A1 true CL2011000295A1 (es) 2011-07-15

Family

ID=41137217

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000295A CL2011000295A1 (es) 2008-08-13 2011-02-11 Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar.

Country Status (16)

Country Link
US (1) US20110190313A1 (enExample)
EP (1) EP2315592A1 (enExample)
JP (1) JP2011530607A (enExample)
KR (1) KR20110053354A (enExample)
CN (1) CN102123711A (enExample)
AU (1) AU2009282104A1 (enExample)
BR (1) BRPI0917491A2 (enExample)
CA (1) CA2732789A1 (enExample)
CL (1) CL2011000295A1 (enExample)
IL (1) IL210922A0 (enExample)
MA (1) MA32617B1 (enExample)
MX (1) MX2011001668A (enExample)
NZ (1) NZ590839A (enExample)
RU (1) RU2011109078A (enExample)
TW (1) TW201010999A (enExample)
WO (1) WO2010019540A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12509424B2 (en) 2019-12-13 2025-12-30 Nippon Shinyaku Co., Ltd. Compound and composition as PDGF receptor kinase inhibitor

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3130908A1 (en) 2009-06-30 2010-12-30 Mallinckrodt Hospital Products IP Limited Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
DK3007689T3 (en) 2013-01-10 2018-06-14 Pulmokine Inc NON-SELECTIVE KINASE INHIBITORS
US20150044288A1 (en) * 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
ES2959419T3 (es) 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
BR112019008622A2 (pt) 2016-10-27 2019-07-09 Pulmokine Inc método para tratar uma condição
AU2017356955B2 (en) 2016-11-08 2023-11-09 Reata Pharmaceuticals Holdings, LLC Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
WO2019157337A1 (en) * 2018-02-08 2019-08-15 Pulmokine, Inc. Formulations of kinase inhibitors and prostanoids
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
SG11202112719XA (en) 2019-05-16 2021-12-30 Aerovate Therapeutics Inc Imatinib formulations, manufacture, and uses thereof
WO2021108303A1 (en) * 2019-11-25 2021-06-03 PHPrecisionMed, LLC Pharmaceutical compositions for the treatment of pulmonary hypertension
WO2022056196A1 (en) * 2020-09-11 2022-03-17 Pulmosim Therapeutics Llc Compositions and methods for treating or preventing pulmonary hypertension
WO2022108939A1 (en) 2020-11-17 2022-05-27 United Therapeutics Corporation Inhaled imatinib for pulmonary hypertension field

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003272007A1 (en) * 2002-10-25 2004-05-13 The Administrators Of The Tulane Educational Fund Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
CN101203224B (zh) * 2005-01-28 2010-11-03 诺瓦提斯公司 嘧啶基氨基苯甲酰胺在制备治疗对Tie-2激酶活性的调节有响应的疾病的药物中的用途
BRPI0611092A2 (pt) * 2005-05-02 2010-08-03 Novartis Ag derivados de pirimidilaminobenzamida para sìndrome hipereosinofìlica
WO2007065898A1 (en) * 2005-12-06 2007-06-14 Novartis Ag Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
AU2007317349B2 (en) * 2006-11-03 2011-10-20 Irm Llc Compounds and compositions as protein kinase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12509424B2 (en) 2019-12-13 2025-12-30 Nippon Shinyaku Co., Ltd. Compound and composition as PDGF receptor kinase inhibitor

Also Published As

Publication number Publication date
US20110190313A1 (en) 2011-08-04
AU2009282104A1 (en) 2010-02-18
CN102123711A (zh) 2011-07-13
CA2732789A1 (en) 2010-02-18
TW201010999A (en) 2010-03-16
JP2011530607A (ja) 2011-12-22
MA32617B1 (fr) 2011-09-01
WO2010019540A1 (en) 2010-02-18
RU2011109078A (ru) 2012-09-20
BRPI0917491A2 (pt) 2015-12-01
MX2011001668A (es) 2011-03-25
NZ590839A (en) 2013-02-22
KR20110053354A (ko) 2011-05-20
IL210922A0 (en) 2011-04-28
EP2315592A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
CL2011000295A1 (es) Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar.
IL280173A (en) Inhibitors of brutons tyrosine kinase
CL2008002478A1 (es) Compuestos derivados de n-fenil-5-(4 haloalcoxi)fenil) pirimidin-2-amino, inhibidores de c-kit y pdgfr; composicion farmaceutica; y su uso en el tratmiento de asma, dermatitis atopica, hipertension pulmonar o arterial, fibrosis renal, pulmonar o cardiaca, entre otras.
CY2016041I1 (el) Αναστολεις κινασης τυροσινης bruton
EA201000094A1 (ru) Производные пиримидинил-пиридазинона
EA200870409A1 (ru) Антагонисты киназы pi3
BRPI0816064A2 (pt) Inibidores da atividade de proteína tirosina cinase.
BR112012008624A2 (pt) inibidores de tirosina quinase de bruton
BRPI0922224A2 (pt) composições de inibidores de proteína tirosina quiinase receptora.
CL2010001483A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
NO20081636L (no) FAP - inhibitorer
BRPI0915231A2 (pt) compostos inibidores de quinase e métodos de uso
EP2040546A4 (en) tyrosine kinase inhibitor
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
EA201100966A1 (ru) Производные пиридазинона
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
EA201100306A1 (ru) Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
AP2012006166A0 (en) Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors.
CL2008001234A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
CY2016017I1 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
CL2013000104A1 (es) Compuestos derivados de heterociclicos nitrogenados sustituidos, agonistas del receptor ip; composicion farmaceutica; combinación farmaceutica; y uso para el tratamiento de la hipertension arterial pulmonar.
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201001648A1 (ru) Производные пиридазинона
EA201170052A1 (ru) Производные тиофена или тиазола и их применение как ингибиторов pi3k